SAB Biotherapeutics's total assets for Q2 2025 were $30.13M, a decrease of -20.96% from the previous quarter. SABS total liabilities were $18.11M for the fiscal quarter, a 8.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.